A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Recruiting

Phase 1

Phase 2

UTI VaccineA Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Sponsor:

GlaxoSmithKline

Code:

NCT06702449

Conditions

Urinary Tract Infections

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Interventions

Candidate UTI vaccine low dose formulation 1

Candidate UTI vaccine low dose formulation 2

Candidate UTI vaccine medium dose formulation 1

Candidate UTI vaccine medium dose formulation 2

Candidate UTI vaccine high dose formulation 1

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-05-13.